Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer
Palliation of Malignant Dysphagia With Spray Cryotherapy in Patients With Advanced Esophageal Cancer: A Pilot Study
Status: Enrolling
Updated:  7/21/2016
Center for Advanced Medicine
mi
from
Saint Louis, MO
Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer
Palliation of Malignant Dysphagia With Spray Cryotherapy in Patients With Advanced Esophageal Cancer: A Pilot Study
Status: Enrolling
Updated: 7/21/2016
Center for Advanced Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Teva Investigational Site 1297
mi
from
Aurora, CO
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Teva Investigational Site 1297
mi
from
Aurora, CO
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Teva Investigational Site 11
mi
from
Detroit, MI
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Teva Investigational Site 11
mi
from
Detroit, MI
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Teva Investigational Site
mi
from
St. Louis, MO
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Teva Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Teva Investigational Site 10183
mi
from
Philadelphia, PA
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Teva Investigational Site 10183
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms
Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms in Early Stage Breast Cancer
Status: Enrolling
Updated:  7/25/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms
Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms in Early Stage Breast Cancer
Status: Enrolling
Updated: 7/25/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy
Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy
Status: Enrolling
Updated:  7/25/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy
Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy
Status: Enrolling
Updated: 7/25/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated:  7/25/2016
Morris Heights Health Center
mi
from
Bronx, NY
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated: 7/25/2016
Morris Heights Health Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated:  7/25/2016
BronwWorks
mi
from
Bronx, NY
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated: 7/25/2016
BronwWorks
mi
from
Bronx, NY
Click here to add this to my saved trials
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated:  7/25/2016
Urban Health Plan
mi
from
Bronx, NY
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated: 7/25/2016
Urban Health Plan
mi
from
Bronx, NY
Click here to add this to my saved trials
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated:  7/25/2016
Montefiore Family Care Center
mi
from
Bronx, NY
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated: 7/25/2016
Montefiore Family Care Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated:  7/25/2016
Good Shepherd Service
mi
from
Bronx, NY
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)
Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project
Status: Enrolling
Updated: 7/25/2016
Good Shepherd Service
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
University of CA at Irvine Chao Cancer Center
mi
from
Orange, CA
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
University of CA at Irvine Chao Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated:  7/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Status: Enrolling
Updated: 7/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
Metformin for Reduction of Paclitaxel Treatment-Related Neuropathy in Patients With Breast Cancer: A Randomized Pilot Study
Status: Enrolling
Updated:  7/25/2016
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
Metformin for Reduction of Paclitaxel Treatment-Related Neuropathy in Patients With Breast Cancer: A Randomized Pilot Study
Status: Enrolling
Updated: 7/25/2016
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer
Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer
Status: Enrolling
Updated:  7/25/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer
Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer
Status: Enrolling
Updated: 7/25/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/25/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/25/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/25/2016
Shands at the University of Florida
mi
from
Gainesville, FL
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/25/2016
Shands at the University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/25/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/25/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/25/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/25/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  7/25/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 7/25/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer
Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer
Status: Enrolling
Updated:  7/26/2016
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer
Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer
Status: Enrolling
Updated: 7/26/2016
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
New Horizons Women's Care
mi
from
Chandler, AZ
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
New Horizons Women's Care
mi
from
Chandler, AZ
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Precision Trials
mi
from
Phoenix, AZ
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Precision Trials
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Arizona OB/GYN Affiliates, PC
mi
from
Phoenix, AZ
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Arizona OB/GYN Affiliates, PC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Visions Clinical Research - Tucson
mi
from
Tucson, AZ
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Visions Clinical Research - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Visions Clinical Research
mi
from
Boynton Beach, FL
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Visions Clinical Research
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Altus Research
mi
from
Lake Worth, FL
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Altus Research
mi
from
Lake Worth, FL
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Center for Women
mi
from
Chicago, IL
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Center for Women
mi
from
Chicago, IL
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Indiana University Dept. of OB/GYN Oncology
mi
from
Indianapolis, IN
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Indiana University Dept. of OB/GYN Oncology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Montefiore Medical Center
mi
from
Bronx, NY
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
New York Downtown Hospital
mi
from
New York, NY
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
New York Downtown Hospital
mi
from
New York, NY
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Temple University
mi
from
Philadelphia, PA
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Temple University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
InVisions Consultants, LLC
mi
from
San Antonio, TX
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
InVisions Consultants, LLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
InVisions Consultants, LLC- c/o Institute for Women's Health
mi
from
San Antonio, TX
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
InVisions Consultants, LLC- c/o Institute for Women's Health
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated:  7/26/2016
Wasatch Clinical Research
mi
from
Salt Lake City, UT
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3
Status: Enrolling
Updated: 7/26/2016
Wasatch Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden
Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden
Status: Enrolling
Updated:  7/26/2016
University of Pittsburgh, Hillman Cancer Center
mi
from
Pittsburgh, PA
Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden
Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden
Status: Enrolling
Updated: 7/26/2016
University of Pittsburgh, Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
Winship Cancer Institute at Emory Midtown
mi
from
Atlanta, GA
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
Winship Cancer Institute at Emory Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
University of Iowa Hospitals & Clinic
mi
from
Iowa City, IA
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
University of Iowa Hospitals & Clinic
mi
from
Iowa City, IA
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
Cleveland Clinic
mi
from
Cleveland, OH
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
University of Pittsburg Hillman Cancer Center
mi
from
Pittsburgh, PA
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
University of Pittsburg Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated:  7/26/2016
Fred Hutchinson Cancer Research Center/Seattle Cancer Care
mi
from
Seattle, WA
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Status: Enrolling
Updated: 7/26/2016
Fred Hutchinson Cancer Research Center/Seattle Cancer Care
mi
from
Seattle, WA
Click here to add this to my saved trials